Thymulin Dosage in the Research Literature

Before the details

There is no human dosing protocol for thymulin, and this page does not provide one. What follows are doses that researchers gave to animals (or added to cells in a dish), described exactly as that — study doses in named species, by a named route. Thymulin is a research peptide, not an approved medicine, so reading this as a regimen would be reading it wrong. The numbers are small (nanograms to low micrograms in rodents), the routes are mostly injection or direct-to-organ, and the human pharmacokinetics are not well characterized.

Thymulin Dosing in the Research Literature

Reported research doses are small and route-specific. In rodent neuroinflammation and analgesia models, thymulin has been given at roughly 0.1 to 1 microgram intracerebroventricular (directly into the brain ventricles) and across a wide 1-to-1000-nanogram range intraperitoneal ^[10]. Intracerebroventricular thymulin in rats reduced hippocampal NF-kB activation in a dose-dependent fashion across a 1-to-25-microgram range ^[10].

In systemic inflammation models, thymulin was given intraperitoneally, often daily or every other day — for example, daily pretreatment for two weeks before an LPS challenge in mice ^[6]. One pancreatic-protection study dosed FTS at 50 micrograms per mouse before LPS ^[11]. These figures are study parameters, not titrations for people. The thymulin peptide dosage question has no answer outside that research context: the public literature does not define a standardized human dose.

How the numbers fit together

Read across studies, the doses share a scale: thymulin is potent enough that effects show up in the nanogram-to-low-microgram range per animal, which is consistent with a hormone acting through high-affinity receptors rather than a bulk agent. Central-nervous-system work clusters at the low end — roughly 0.1 to 1 microgram intracerebroventricular for analgesia and neuroinflammation, with NF-kB suppression reported across a 1-to-25-microgram i.c.v. range ^[10]. Systemic models run higher and longer, with intraperitoneal dosing given daily or every other day ^[6], and the pancreatic-protection study used 50 micrograms per mouse before the LPS challenge ^[11].

The units matter as much as the magnitudes. A microgram into a mouse brain and a microgram into a person are not comparable quantities, and dividing by body weight does not make a research dose a human dose. The literature reports these as experimental parameters; this page reports them the same way. There is no validated human protocol to scale them to.

How is thymulin administered in research?

Routes used in studies include intraperitoneal, subcutaneous, intracerebroventricular, intratracheal (for gene therapy), intramuscular (for gene-therapy vectors), topical (a small zinc-thymulin pilot), and in vitro ^[7][11]. The route is rarely incidental — it tracks the question being asked. Brain-inflammation work goes intracerebroventricular to put the peptide where it is being studied ^[10]; systemic inflammation work goes intraperitoneal ^[6]; the asthma work goes intratracheal because the target is the lung ^[7].

A recurring theme is that the most ambitious delivery work does not administer the peptide at all. Gene-therapy approaches deliver a vector — an adenoviral construct or a nanoparticle-borne plasmid — that instructs the animal's own cells to express thymulin, precisely because the native peptide is short-lived ^[5][7]. In one such design, a synthetic active analog (metFTS) was cloned into regulatable adenovectors so circulating thymulin could be restored and, in principle, switched up or down ^[5]. That is a fundamentally different intervention from injecting a dose of peptide, and it should not be read as one.

What is the half-life of thymulin?

As a small peptide, native thymulin has a short circulating half-life ^[4]. Its precise human pharmacokinetic half-life, however, is not well established in the public literature. The clearest indirect evidence is strategic: gene-therapy approaches were developed specifically to sustain circulating thymulin levels over time, which only makes sense for a molecule that does not persist on its own ^[5][7]. Precise half-life claims about native thymulin in humans are not something this record can support, and a confident number in a consumer source is a number to distrust.

Is There a Thymulin Supplement?

No. Thymulin is not a dietary supplement; it is handled as a research peptide for laboratory use ^[4]. Because its activity depends entirely on zinc, much of the human-relevant literature concerns zinc status and its effect on the body's own thymulin rather than supplementing the peptide ^[3]. In mild human zinc deficiency, serum thymulin activity fell and was corrected by zinc repletion ^[3] — a finding about endogenous thymulin and zinc, not about taking thymulin itself.

What human dosing data exist

The honest answer to "what dose do people use" is that the human record is too thin and too old to define one. The historical human work that exists used synthetic analogs and the zinc-bound form rather than a standardized native-thymulin protocol: early controlled and open trials studied a synthetic analog and FTS-Zn in rheumatoid arthritis, and a small open-label pilot looked at topical zinc-thymulin ^[4]. None of that constitutes a modern, well-powered human dosing study of native thymulin, and the specific numbers from small single-source pilots should be treated as preliminary rather than established.

The more durable human-relevant finding is indirect and concerns the body's own thymulin: in mild zinc deficiency, serum thymulin activity fell and was restored by zinc repletion ^[3]. That is a result about zinc and endogenous thymulin, not a dosing recommendation for the peptide. The literature simply does not provide a validated human dose, and this page will not invent one.

Stability and the zinc condition

One handling fact follows directly from the mechanism. Thymulin's activity requires its bound zinc ion: chelation with agents such as EDTA or Chelex abolishes activity, and the apopeptide is inactive until zinc is restored ^[1]. Any meaningful discussion of thymulin's behavior — in storage, in assay, in any model — has to account for the zinc that defines it — the role of zinc in thymulin activity is covered in full on its own page.